AS OF Feb 29, 2024
Pursuant to NRS 78.315 of the General Corporation Law of the State of Nevada, the undersigned, being all of the directors of Kiwa Bio-Tech Products Group Corporation, a Nevada corporation (the “Company”), acting without a meeting, and waiving any required notice, do hereby unanimously adopt the following corporate resolutions and do hereby unanimously consent to the taking of the actions therein set forth, which resolutions will be deemed adopted when all of the directors have signed this consent.
WHEREAS, Ms. Wang Ziqi resigns from the position of Chairman and Chief Executive Officer and Director in the company, and Mr. Jiang is newly appointed as Chairman and Chief Executive Officer and Director by the company.
RESOLVED, commencing Feb 29, 2024. the Board of Directors has appointed Mr. Shanghua Jiang to act as Chairman and Chief Executive Officer and Director.
RESOLVED FURTHER, that the Board of Directors authorizes the Company to enter into an Employment Agreement with Mr.Jiang in the form attached hereto as Exhibit “A” .
RESOLVED FURTHER, that the officers of the Company be, and each of them individually hereby is, authorized, empowered and directed, to execute any and all such certificates, amendments, instruments and documents, in the name of, and on behalf of, the Company, with such changes thereto as any officer may approve, and to take all such further action as they, or any ofthem, may deem necessary or appropriate to carry out the purpose and intent of the foregoing resolutions.
IN WITNESS, the undersigned have executed this Unanimous Consent of Directors in Lieu of Meeting as of the first date written above.
(SIGNATURE PAGE FOLLOWS)
Forward-Looking Statements
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the U.S. Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company’s actual results may differ materially from those anticipated in the forward-looking statements depending on a number of risk factors including, but not limited to, the following: general economic, business and environment conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, the execution of its ten-year growth plan, the foreign exchange risk amid the unexpected announcements by the PRC government and various other factors beyond the Company’s control. Kiwa Bio-Tech Products Group Corp. specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
For investor and media inquiries, please contact:
Email: wangziqi352442220@126.com
